Research Compound Overview

5-Amino-1MQ Research: NNMT Inhibition & NAD+ Metabolism

Last updated: June 11, 2026 · Small-molecule NNMT inhibitor

5-Amino-1MQ (5-amino-1-methylquinolinium) is a small-molecule research compound from the methylquinolinium chemical class. Unlike the peptides that make up most of the metabolic research catalog, it is a low-molecular-weight, membrane-permeable molecule designed for a single, well-defined job in the laboratory: inhibiting the enzyme nicotinamide N-methyltransferase (NNMT). That enzyme sits at a busy metabolic intersection — it links the cell's methylation economy to its NAD+ supply — which is why a compound that simply turns NNMT down has become a recurring tool in published metabolic and aging research.

The research interest traces to a specific observation: NNMT is markedly elevated in the fat tissue of obese animals and humans, and lowering NNMT activity — first by genetic knockdown, later with small-molecule inhibitors including 5-Amino-1MQ — has been associated with changes in body composition in rodent models. This article summarizes what the published literature actually shows, where the evidence is strong, and, just as importantly, where it is thin.

Chemical Profile

How NNMT Works — and Why Inhibiting It Matters

The enzyme that taxes two currencies at once

NNMT catalyzes one reaction: it transfers a methyl group from S-adenosylmethionine (SAM) onto nicotinamide, producing 1-methylnicotinamide (1-MNA) and S-adenosylhomocysteine (SAH). That single reaction draws down two of the cell's most important metabolic currencies simultaneously. SAM is the universal methyl donor used in DNA, histone, and protein methylation. Nicotinamide is a precursor the cell would otherwise recycle back into NAD+ through the salvage pathway.

When NNMT activity is high, more nicotinamide is permanently methylated and excreted as 1-MNA instead of being salvaged, and more SAM is consumed. When NNMT activity is low, both currencies are spared. This is the mechanistic logic behind NNMT inhibition: a compound like 5-Amino-1MQ does not add NAD+ or SAM to the cell — it stops a drain on them.

The NAD+ connection

Because nicotinamide is a salvage-pathway precursor to NAD+, reducing NNMT-mediated methylation leaves more nicotinamide available for NAD+ regeneration. NAD+ is the coenzyme that powers sirtuins, supports mitochondrial electron transport, and serves hundreds of metabolic reactions — the same biology covered in depth in the NAD+ research overview. Published work in adipose models has linked NNMT knockdown to higher cellular NAD+ and increased oxygen consumption, framing NNMT inhibition as an indirect way to influence NAD+ availability and energy expenditure in fat cells.

The Adipose & Metabolic Research Story

The foundational finding came from genetics, not chemistry. In a 2014 study published in Nature, researchers used antisense knockdown to lower NNMT specifically in the white adipose tissue and liver of mice. Knockdown animals were protected against high-fat-diet-induced weight gain, with the authors reporting shifts in adipose SAM and NAD+ levels and increased cellular energy expenditure. This established NNMT as a genuine metabolic regulator in fat tissue, not merely a biomarker.

The question that followed was whether a drug-like molecule could reproduce the genetic effect. A medicinal-chemistry program characterized the methylquinolinium scaffold — the chemical family to which 5-Amino-1MQ belongs — identifying small molecules with low-micromolar potency against NNMT and the structure-activity relationships behind them.

The most directly relevant report came in 2018, when researchers administered membrane-permeable small-molecule NNMT inhibitors — including 5-Amino-1MQ — to diet-induced-obese mice. The compounds were associated with reduced body weight, lower white-adipose-tissue mass, and smaller adipocyte size, notably without a measured change in food intake — pointing to a metabolic rather than appetite-mediated effect in that model. This is the single study most often cited as the primary characterization of 5-Amino-1MQ in a whole animal.

Beyond Fat: The Aged-Muscle Finding

NNMT research is not limited to adipose tissue. In a 2019 study, the same research group reported that a small-molecule NNMT inhibitor influenced senescent muscle stem cells and the regenerative capacity of aged skeletal muscle in mice. After chemically induced injury, treated aged animals showed larger regenerating-fiber cross-sectional area and improved measures of muscle function versus controls, with parallel effects on myoblast differentiation and the NAD+/NADH redox state in culture. This extended the NNMT-inhibition concept from metabolism into aging and tissue-regeneration research.

Human Relevance — of the Target, Not the Compound

It is important to separate two things: the human evidence for NNMT biology, and the human evidence for 5-Amino-1MQ. The former exists; the latter does not. In a 2015 study across multiple human cohorts, adipose-tissue NNMT expression was roughly twofold higher in people with type 2 diabetes than in controls and correlated inversely with insulin sensitivity. This human association strengthens the rationale for studying NNMT — but it studies the enzyme, not the inhibitor.

Several peer-reviewed reviews summarize the broader NNMT field — the enzyme's place at the crossroads of metabolism and epigenetic regulation, its candidacy as a metabolic-syndrome target, and its relevance to aging research — and are useful entry points to the wider literature.

Research Formats: Powder and Oral Tablet

Because 5-Amino-1MQ is a small, stable, membrane-permeable molecule rather than a peptide, it is handled differently from the lyophilized peptides elsewhere in the catalog. Two research formats are catalogued. The 10mg lyophilized powder suits in vitro work where investigators prepare their own stock solutions, typically reconstituting in DMSO or ethanol. The 30mg oral tablet (120-count) is a solid finished format used where a pre-measured, orally relevant presentation is preferred for a research protocol. Both are supplied strictly for laboratory research; neither is formulated, labeled, or intended for human consumption.

Dosing in Research Settings

Published 5-Amino-1MQ work is conducted in cell culture and rodent models, where investigators define exposures appropriate to their system — micromolar concentrations in vitro, and investigator-determined systemic regimens over multi-week protocols in diet-induced-obese or aged mice. These are species- and model-specific research parameters reported in the primary literature. They are not human dosing guidance, and nothing here should be read as such; there are no established human protocols for this compound.

Research Limitations — an Honest Accounting

The NNMT mechanism is well-characterized and supported by genetic, biochemical, and human-association data. The evidence for 5-Amino-1MQ specifically is early and exclusively preclinical. The primary in-animal data come from a small number of studies, largely from a single research group, in cell and rodent models. There are no published human clinical trials of 5-Amino-1MQ, and human data on the compound itself — as opposed to the NNMT target — is essentially absent. Open questions include long-term effects, tissue selectivity of inhibition, and how rodent metabolic findings would translate. Researchers should treat the compound as an investigational tool and weight the literature accordingly.